Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD is drawing significant interest across the industry.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the SINERGY trial, a Phase 2 study in recu...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- If Big Tech cared about fighting AI slop, it wouldn’t be drowning us in it
- Secunderabad Cantonment merger plea sent to defence ministry, say officials
- The rich pay me $150k to teach their spoiled kids to be less SELFISH. Offenses range from out-of-control spending to cheating... but here's why I actually feel sorry for them
- WHO designates new Collaborating Centre to strengthen evidence and integration of traditional medicine
Source: Original →